An mRNA construct encoding targets identified from one patient's own tumor. Unlike vaccines directed at a shared antigen, each construct is designed and manufactured for a single individual based on that person's sequencing data.

No. Individualized mRNA cancer vaccines are investigational. No such product has received FDA approval; Phase 3 programs from Moderna, Merck, and BioNTech are ongoing. Echo's constructs have been administered under FDA-accepted pathways at academic medical centers, with sponsor-investigator oversight and IRB approval.

mRNA and lipid nanoparticle delivery have established clinical safety records across multiple indications. In published trials of individualized cancer vaccines, reported adverse events have been predominantly low-grade and transient.

These findings are based on published studies of other investigational products and do not constitute a safety claim about Echo's constructs, which remain under evaluation.

Yes. Echo dosed its first patient in June 2026, under a single-patient IND with sponsor-investigator oversight at an academic medical center. Antigen-specific T-cell responses to selected epitopes are being measured as part of immune monitoring. Immunogenicity is a pharmacodynamic finding and is not evidence of clinical benefit.

Treating physicians can contact Echo through the form on this page. Patients interested in Echo's programs should discuss them with their treating oncologist.